organization · Reporting owner
ATP Life Science Ventures, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
Jointly reported with ATP III GP, Ltd.
Section 16 reporting ended · disclosed 2021-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-28 · Other · Disposed 5,830,203 · Balance 0 F1: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.). F2: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.).
F2: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.
Stoke Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
Jointly reported with ATP III GP, Ltd.
Section 16 reporting ended · disclosed 2021-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-28 · Other · Disposed 17,161,713 · Balance 0 F1: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.). F2: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.).
F2: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2021 Filed Jun 30, 2021 16:31 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | OtherCommon Stock | 5,830,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-006112 · form4.xml · nonDerivative · entry 1 ATP Life Science Ventures, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.). F1 · price: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.). F2 · ownership.direct: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:32 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | OtherCommon Stock | 17,161,713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-006113 · form4.xml · nonDerivative · entry 1 ATP Life Science Ventures, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.). F1 · price: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.). F2 · ownership.direct: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | PurchaseCommon Stock | 375,000 | $39.00 | $14,625,000.00 |
DisclosureSEC source: 0001209191-20-060542 · doc4.xml · nonDerivative · entry 1 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,161,713 F1 · ownership.direct: Represents shares held by Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III") is the sole general partner of ATP IV. Seth Harrison, a director of the issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV, but disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 16:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 415,000 | $36.00 | $14,940,000.00 |
DisclosureSEC source: 0001104659-20-083455 · a4.xml · nonDerivative · entry 1 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,830,203 F1 · shares: On July 10, 2020, Apple Tree Partners, IV, L.P. ("ATP") purchased 415,000 shares of common stock of the Issuer at a price of $36.00 per share pursuant to an underwritten public offering. F2 · ownership.direct: These shares are owned directly by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionSeries B Preferred Stock · Derivative | 880,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037457 · a4.xml · derivative · entry 5 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 286,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.direct: These shares are owned directly by ATP. ATP III GP, Ltd.("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionSeries A Preferred Stock · Derivative | 13,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037457 · a4.xml · derivative · entry 4 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,228,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.direct: These shares are owned directly by ATP. ATP III GP, Ltd.("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 900,000 | $16.00 | $14,400,000.00 |
DisclosureSEC source: 0001104659-19-037457 · a4.xml · nonDerivative · entry 3 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,415,203 F5 · shares: On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F4 · ownership.direct: These shares are owned directly by ATP. ATP III GP, Ltd.("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionCommon Stock | 286,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-037457 · a4.xml · nonDerivative · entry 2 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,515,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.direct: These shares are owned directly by ATP. ATP III GP, Ltd.("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionCommon Stock | 4,228,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-037457 · a4.xml · nonDerivative · entry 1 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,228,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. ("ATP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.direct: These shares are owned directly by ATP. ATP III GP, Ltd.("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,799,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · derivative · entry 7 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,799,910 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 7,617,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · derivative · entry 6 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,617,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,980,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · derivative · entry 5 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,980,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | PurchaseCommon Stock | 1,388,889 | $18.00 | $25,000,002.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · nonDerivative · entry 4 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,786,713 F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionCommon Stock | 2,799,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · nonDerivative · entry 3 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,397,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionCommon Stock | 7,617,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · nonDerivative · entry 2 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,597,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionCommon Stock | 4,980,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013838 · doc1.xml · nonDerivative · entry 1 Apple Tree Partners IV, L.P. · CIK 0001593440 · 10% owner ATP III GP, Ltd. · CIK 0001593453 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,980,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.direct: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.